Reshma Kewalramani - Vertex Pharmaceuticals President

VRTX -- USA Stock  

USD 176.14  1.98  1.11%

  President
Dr. Reshma Kewalramani M.D. was appointed as President, Chief Executive Officer, Director of the company. Effective April 01, 2020. and she is no longer as an Executive Vice President Global Medicines Development and Medical Affairs, Chief Medical Officer of the Company, Effective April 01, 2020. She was our Senior Vice President, Late Development from February 2017 until April 2018. From August 2004 to January 2017 she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President Global Clinical Development, Nephrology Metabolic Therapeutic Area and as Vice President, U.S. Medical Organization. Dr. Kewalramani is the industry representative to the FDAs Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Womens Hospital combined program
Age: 45  President Since 2018      
617-341-6100  http://www.vrtx.com
Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine.

Reshma Kewalramani Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 9.99 % which means that it generated profit of $9.99 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 56.25 % meaning that it created $56.25 on every $100 dollars invested by stockholders.
The company currently holds 656.95M in liabilities with Debt to Equity (D/E) ratio of 12.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.67 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Andrew FentonZoetis
2018
Daniel PlewRegeneron Pharmaceuticals
2016
Scott JamisonPerrigo Company plc
2011
Grainne QuinnPerrigo Company plc
2016
Ganadhish KamatDr Reddys Laboratories Ltd
2016
Sandra BeatyZoetis
2012
Svend AndersenPerrigo Company plc
2017
Peter PowchikRegeneron Pharmaceuticals
2006
Clinton LewisZoetis
2018
Joseph LaRosaRegeneron Pharmaceuticals
2019
Alok SonigDr Reddys Laboratories Ltd
2015
Saumen ChakrabortyDr Reddys Laboratories Ltd
2018
Kristin PeckZoetis
2018
Michael AbermanRegeneron Pharmaceuticals
2015
Stefan WeiskopfZoetis
2013
Glenn DavidZoetis
2016
Umang VohraDr Reddys Laboratories Ltd
2013
Catherine KnuppZoetis
2012
Marc CouckePerrigo Company plc
N/A
John WesolowskiPerrigo Company plc
2016
Marion McCourtRegeneron Pharmaceuticals
2018

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Current Sentiment - VRTX

Vertex Pharmaceuticals Investor Sentiment

Most of Macroaxis users are at this time bullish on Vertex Pharmaceuticals Incorpor. What is your outlook on investing in Vertex Pharmaceuticals Incorpor? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased one share of
few hours ago
Traded for 1221.15
Purchased over 100 shares of
few hours ago
Traded for 19.55
Purchased over 40 shares of
few hours ago
Traded for 43.23
Also please take a look at World Market Map. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Search macroaxis.com